Refractory epilepsy: A clinically oriented review

European Neurology

Volumn 62, Issue 2, 2009, Pages 65-71

  Beleza, Pedro ^a,b  

^a Sao Marcos Hospital   (Portugal)

^b HOSPITAL DE BRAGA   (Portugal)

Author keywords

Epilepsy surgery; Neurology; Refractory epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; TOPIRAMATE; ZONISAMIDE;

BRAIN DEPTH STIMULATION; BRAIN HEMORRHAGE; BRAIN SURGERY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; CORPUS CALLOSUM TRANSSECTION; CORTICAL DYSPLASIA; DISEASE CONTROL; DRUG TOLERABILITY; EPILEPSY; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEMISPHERECTOMY; HIPPOCAMPAL SCLEROSIS; HUMAN; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SEIZURE; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION;

AGE OF ONSET; ANTICONVULSANTS; BRAIN; EPILEPSY; HUMANS; INTRACRANIAL HEMORRHAGES; MALFORMATIONS OF CORTICAL DEVELOPMENT; RISK FACTORS; SCLEROSIS;

EID: 66749083885     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000222775     Document Type: Review

References (60)

1. Kwan P, Sander JW: The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 2004; 75: 1376 -1381.
2. Schuele SU, Luders HO: Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008; 7: 514 -52 4 .
3. Hauser WA, Hesdorffer DC: Epidemiology of intractable epilepsy; in Luders H (ed): Epilepsy Surgery. New York, Raven Press, 1992, pp 55-59.
4. Kwan P, Brodie MJ: Early identification of refractor y epi lepsy. N Engl J Med 2000; 342: 314 -319.
5. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA: Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62:382-389.
6. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B: Early development of intractable epilepsy in children: a prospective study. Neurology 2001; 56:1445-1452.
7. Starreveld E, Guberman A: The spectrum of intractable epilepsy: a proposed scale. Adv Neurol 2006; 97:493-496.
8. Sillanpaa M, Jalava M, Shinnar S: Epilepsy syndromes in patients with childhood-onset seizures in Finland. Pediatr Neurol 1999; 21: 533-537.
9. Mohamed IS, Minassian BA: What intractability information is there in the type of generalized seizure? Adv Neurol 2006; 97: 14 1- 147.
10. Blume WT: Focal seizures: intractability and semiology. Adv Neurol 2006; 97:17-25.
11. Hauser WA, Kurland LT: The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16:1-66.
12. Cain DP: Kindling and the amygdala; in Aggleton JP (ed): The Amygdala: Neurobio-logical Aspects of Emotion, Memory and Mental Dysfunction. New York, Wiley-Liss, 1992, pp 539-560.
13. Ebersole J, Chatt A: Spread and arrest of seizures: the importance of layer 4 in laminar interactions during neocortical epileptogen-esis; in Delgado-Escueta AV, Ward AA Jr, Woodbury DM, Porter RJ (eds): Basic Mechanisms of the Epilepsies: Molecular and Ce-lullar Approaches. Advances in Neurology. New York, Raven Press, 1986, vol 44, pp 515- 558.
14. Williamson P, Wieser HG, Delgado-Escueta AV: Clinical characteristics of partial seizures; in Engel J Jr (ed): Surgical Treatment of the Epilepsies. New York, Raven Press, 1987, pp 101-120.
15. Schiller Y, Najjar Y: Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70: 54-65.
16. Ko TS, Holmes GL: EEG and clinical predictors of medically intractable childhood epilepsy. Clin Neurophysiol 1999; 110: 1245- 1251.
17. Mikuni N, Nishiyama K, Babb TL, Ying Z, Najm I, Okamoto T, Luders HO, Wylie C: Decreased calmodulin-NR1 co-assembly as a mechanism for focal epilepsy in cortical dysplasia. Neuroreport 1999; 10:1609-1612.
18. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Bro-die MJ: Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007; 75:192-196.
19. Kim WJ, Park SC, Lee SJ, Lee JH, Kim JY, Lee BI, Kim DI: The prognosis for control of seizures with medications in patients with MRI evidence for mesial temporal sclerosis. Epilepsia 1999; 40: 290 -293.
20. Rosati A, Aghakhani Y, Bernasconi A, Olivier A, Andermann F, Gotman J, Dubeau F: Intractable temporal lobe epilepsy with rare spikes is less severe than with frequent spikes. Neurology 2003; 60:1290-1295.
21. Wada K, Kiryu K, Kawata Y, Chiba T, Mizu-no K, Okada M, Tasaki H, Fukushima Y, Saito F, Kaneko S: Prognosis and clinical features of intractable epilepsy: a prospective study. Psychiat r y Clin Neurosci 1997; 51: 233-235.
22. Binnie CD, Rowan AJ, Overweg J, Meinardi H, Wisman T, Kamp A, Lopes da Silva F: Telemetric EEG and video monitoring in epilepsy. Neurology 1981; 31:298-303.
23. Cascino GD: Video-EEG monitoring in adu lts. Epilepsia 2002; 43(suppl 3):80 -93.
24. Brodie MJ: Diagnosing and predicting refractory epilepsy. Acta Neurol Scand Suppl 2005; 181 : 36-39.
25. Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC: Nonadherence to antiepi-leptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008; 71: 1572-1578.
26. Bourgeois BFD: General concepts of medical intractability; in Lüders HO (ed): Epilepsy Surgery. Philadelphia, Lippincott, Williams & Wilkins, 2001, pp 63-68.
27. Rosenow F, Luders H: Presurgical evaluation of epilepsy. Brain 2001; 124: 16 8 3 -17 0 0 .
28. Engel J, Cascino G, Shields W: Surgically remediable syndromes; in Engel J, Pedley TA (eds): Epilepsy: A Comprehensive Textbook. Philadelphia, Lippincot-Raven, 1997, pp 1687-1696.
29. Wiebe S, Blume WT, Girvin JP, Eliasziw M: A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345: 311-318 .
30. Duncan JS: Epilepsy surgery. Clin Med 2007; 7:137-142.
31. Jeha LE, Najm IM, Bingaman WE, Khand-wala F, Widdess-Walsh P, Morris HH, Dinner DS, Nair D, Foldvary-Schaeffer N, Pray-son RA, Comair Y, O'Brien R, Bulacio J, Gupta A, Luders HO: Predictors of outcome after temporal lobectomy for the treatment of intractable epilepsy. Neurology 2006; 66: 1938-1940.
32. Spencer S, Huh L: Outcomes of epilepsy surgery in adults and children. Lancet Neurol 2008; 7:525-537.
33. McIntosh AM, Kalnins RM, Mitchell LA, Fabinyi GC, Briellmann RS, Berkovic SF: Temporal lobectomy: long-term seizure outcome, late recurrence and risks for seizure recurrence. Brain 2004; 127: 2018-2030.
34. Aull-Watschinger S, Pataraia E, Czech T, Baumgartner C: Outcome predictors for surgical treatment of temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 2008; 49: 1308-1316.
35. Mosewich RK, So EL, O'Brien TJ, Cascino GD, Sharbrough FW, Marsh WR, Meyer FB, Jack CR, O'Brien PC: Factors predictive of the outcome of frontal lobe epilepsy surgery. Epilepsia 2000; 41:843-849.
36. Jeha LE, Najm I, Bingaman W, Dinner D, Widdess-Walsh P, Luders H: Surgical outcome and prognostic factors of frontal lobe epilepsy surgery. Brain 2007; 130:574-584.
37. Gonzalez-Martinez JA, Gupta A, Kotagal P, Lachhwani D, Wyllie E, Luders HO, Bingaman WE: Hemispherectomy for catastrophic epilepsy in infants. Epilepsia 2005; 46: 1518 -1525.
38. Morris GL 3rd, Mueller WM: Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 1999; 53:1731-1735.
39. Spencer SS, Spencer DD, Williamson PD, Sass K, Novelly RA, Mattson RH: Corpus callosotomy for epilepsy. I. Seizure effects. Neurology 1988; 38:19-24.
40. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH: The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008; 7:500- 506.
41. Luciano AL, Shorvon SD: Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62:375-381.
42. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA: Efficacy and toler-ability of the new antiepileptic drugs. II. Treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62:1261-1273.
43. Berg AT, Langfitt J, Shinnar S, Vickrey BG, Sperling MR, Walczak T, Bazil C, Pacia SV, Spencer SS: How long does it take for partial epilepsy to become intractable? Neurology 2003; 60:186 -190.
44. Schmidt D, Loscher W: Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epi lepsia 2005; 46: 858-877.
45. Goodridge DM, Shorvon SD: Epileptic seizures in a population of 6,000. II. Treatment and prognosis. Br Med J (Clin Res Ed) 1983; 287:645-647.
46. Sillanpaa M, Schmidt D: Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 20 06; 129: 617- 624.
47. Anderson GD, Shen DD: Where is the evidence that P-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? Epilepsia 2007; 48:2372-2374.
48. Leschziner GD, Andrew T, Leach JP, Chad-wick D, Coffey AJ, Balding DJ, Bentley DR, Pirmohamed M, Johnson MR: Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. Pharmacogenet Genomics 2007; 17:217-220.
49. Jandova K, Pasler D, Antonio LL, Raue C, Ji S, Njunting M, Kann O, Kovacs R, Meencke HJ, Cavalheiro EA, Heinemann U, Gabriel S, Lehmann TN: Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain 2006; 129:3290-3306.
50. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102:5507-5512.
51. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C: ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007; 48(suppl 5):140- 149.
52. Remy S, Beck H: Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006; 129:18-35.
53. Rogawski MA, Johnson MR: Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008; 8: 127-130.
54. Nilsen KE, Cock HR: Focal treatment for refractory epilepsy: hope for the future? Brain Res Brain Res Rev 2004; 44: 14 1 -1 53 .
55. Kwan P, Brodie MJ: Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006; 6:397-406.
56. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K: Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev 2008;CD007294.
57. Tamargo RJ, Rossell LA, Kossoff EH, Tyler BM, Ewend MG, Aryanpur JJ: The intracere-bral administration of phenytoin using con-trolled-release polymers reduces experimental seizures in rats. Epilepsy Res 2002; 48: 14 5 -155 .
58. Chabardés S, Minotti L, Chassagnon S, Piallat B, Torres N, Seigneuret E, Vercueil L, Carron R, Hirsch E, Kahane P, Benabid AL: Basal ganglia deep-brain stimulation for treatment of drug-resistant epilepsy: review and current data (in French). Neurochirurgie 2008; 54: 436-440.
59. Stein AG, Eder HG, Blum DE, Drachev A, Fisher RS: An automated drug delivery system for focal epilepsy. Epilepsy Res 2000; 39: 103-114.
60. Mormann F, Andrzejak RG, Elger CE, Lehnertz K: Seizure prediction: the long and winding road. Brain 2007; 130 : 314 -333.